Device Trial Radar · NCT06590467
Abbott Structural Heart Device Registry
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,500
Planned (sponsor's estimate)
Start
Aug 21, 2024
Primary completion
Dec 2029
Study completion Nov 2039
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Abbott Structural Heart (SH) Registry is being conducted to confirm the safety and performance of Abbott's SH devices in a post-market, real-world setting. The Registry primarily involves gathering data from routine hospital practices and standard-of-care (SOC) procedures administered to patients. All devices used in these procedures must be commercially available to the participating site. A list of specific devices covered by the Registry are available upon request from the Sponsor. Data generated by the Registry will be used to meet regulatory requirements, such as the European Union Medical Device Regulations 2017/745, that require active post-market clinical follow-up (PMCF) for all commercially available devices.
Conditions
- Heart Diseases
- ASD - Atrial Septal Defect
- VSD - Muscular Ventricular Septal Defect
- PFO - Patent Foramen Ovale
- PIVSD - Post Infarct Muscular Ventricular Septal Defect
- Valvular Heart Disease
Interventions
Amplatzer™ Occlusion DevicesDevice
The Amplatzer™ Occluders are devices intended for the occlusion of multiple septal heart defects.
Epic™ Surgical Tissue Heart Valve devicesDevice
The Epic™ valves are indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native aortic/mitral heart valve. It may also be used as a replacement for a previously implanted aortic/mitral prosthetic heart valve.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Safety EndpointTime frame: 7 days
- Primary Effectiveness EndpointTime frame: Baseline
Locations
36 sites in 10 countries. Site status is shown where the registry gives one.
USC University Hospital
Los Angeles, California · Not yet recruiting
MedStar Washington Hospital Center
Washington D.C., District of Columbia · Not yet recruiting
Baptist Hospital of Miami
Miami, Florida · Not yet recruiting
33 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.